NeurologyLive® Friday 5 — June 21, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Analyzing Long-Term, End-Of-Study Results for Inebilizumab Treatment in NMOSD: Bruce Cree, MD, PhD, MAS, FAAN

The clinical research director of the UCSF Multiple Sclerosis Center discussed findings from the end-of-study analysis assessing inebilizumab which revealed a significant reduction in attack rates among patients with NMOSD over time. [WATCH TIME: 3 minutes]

2: Innovative Wearables to Tackle Bladder Dysfunction in Multiple Sclerosis: Valerie J. Block, PT, DPTSc

The assistant professor of neurology at UCSF Weill Institute for Neurosciences talked about a study that explored the use of commercial wearable devices to monitor and manage bladder dysfunction in multiple sclerosis. [WATCH TIME: 6 minutes]

3: Eliciting Patient Voice to Help Optimize the Treatment and Management of Cataplexy: Anne Marie Morse, DO, FAASM

The pediatric neurologist and sleep medicine specialist at Geisinger Medical Center provided commentary on the complexities with treating cataplexy, and the misperceptions patients may have about how to manage their condition. [WATCH TIME: 3 minutes]

4: NeuroVoices: Alessio Travaglia, PhD, on New FNIH Partnership to Accelerate ALS Biomarkers, Research

In this week's NeuroVocies Q&A, the director at the Foundation for the National Institutes of Health provided commentary on a recently launched partnership aimed at building a repository of ALS data to advance drug development for the disease.

5: The Broader Impact of Eptinezumab for Chronic Migraine Management: Fawad Khan, MD, FACNS, FAHS

The director of The McCasland Family Comprehensive Headache Center talked about findings from a study that explored the effect of eptinezumab treatment in a broader chronic migraine population. [WATCH TIME: 6 minutes]